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Background: The sentinel lymph node (SLN) biopsy technique is a reliable means of deter-
mining the tumor-harboring status of regional lymph nodes in melanoma patients. When
technetium99 m-labeledantimonytrisulﬁdecolloid(
99 mTc-Sb2S3)particlesareusedtoperform
preoperative lymphoscintigraphy for SLN identiﬁcation, they are retained in the SLN but are
absentorpresentinonlytinyamountsinnon-SLNs.Thepresentstudyinvestigatedthepotential
for a novel means of assessing the accuracy of surgical identiﬁcation of SLNs. This involved the
use of inductively coupled plasma–mass spectrometry (ICP-MS) to analyze antimony concen-
trations in fine-needle biopsy (FNB) samples from surgically procured lymph nodes.
Methods: A total of 47 FNB samples from surgically excised lymph nodes (32 SLNs and 15
non-SLNs) were collected. The SLNs were localized by preoperative lymphoscintigraphy that
used
99 mTc-Sb2S3,bluedye,andgammaprobetechniques.Theconcentrationsofantimonywere
measured in the FNB samples by ICP-MS.
Results: The mean and median antimony concentrations (in parts per billion) were .898 and
.451 in the SLNs, and .015 and .068 in the non-SLNs, the differences being highly statistically
signiﬁcant (P < .00005).
Conclusions: Our results show that ICP-MS analysis of antimony concentrations in FNB
specimens from lymph nodes can accurately conﬁrm the identity of SLNs. Used in conjunction
with techniques such as proton magnetic resonance spectroscopy for the nonsurgical evaluation
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934of SLNs, ICP-MS analysis of antimony concentrations in FNB samples could potentially serve
as a minimally invasive alternative to surgery and histopathologic evaluation to objectively
classify a given node as sentinel or nonsentinel and determine its tumor-harboring status.
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The sentinel lymph node (SLN) biopsy technique,
introduced in the early 1990s, has made it possible to
establish the tumor-harboring status of the regional
node ﬁeld in melanoma patients with a minimally
invasive procedure.
1 Within 3 years of the publica-
tion describing the procedure, the accuracy of SLN
biopsy was conﬁrmed in two further studies in which
the SLN status was found to accurately reﬂect the
status of the entire lymph node ﬁeld.
2,3 The SLN
biopsy technique has since become widely accepted as
a method of staging the disease of patients with
melanoma who have clinically negative lymph nodes.
The status of the SLN is used to determine whether
further surgical or adjuvant therapy is appropriate,
and to assess patient prognosis. The tumor-harboring
status of the SLN is the single most important
prognostic factor for melanoma patients, surpassing
Breslow thickness, ulceration, and mitotic rate.
4
To provide accurate prognostic information and to
guide appropriate management, it is imperative that
all ‘‘true’’ SLNs are accurately identiﬁed, excised, and
assessed for their tumor-harboring status. In a num-
ber of cases, a false-negative result may occur,
whereby a patient with disease originally assessed as
SLN-negative subsequently develops recurrence in a
regional node ﬁeld. It is disturbing to note that false-
negative rates of up to 24.8% have been reported
from some major melanoma treatment centers and
cooperative groups.
5–16 Available evidence suggests
that these failures occur not because the SLN biopsy
concept is ﬂawed, but because of methodological and
technical shortcomings in nuclear medicine, surgery,
and histopathology.
In an attempt to identify how many of these false-
negative cases might have been because of surgical
failures—that is, the removal of a lymph node that
was not the SLN identiﬁed by the preoperative lym-
phoscintigraphy—we have developed a technique for
assaying antimony in tissue sections. This work is
based on the concept that technetium 99 m–labeled
antimony trisulfide colloid (
99 mTc-Sb2S3) particles
used for preoperative lymphoscintigraphy in Austra-
lia are retained in the SLN but are absent or present in
only tiny amounts in non-SLNs. It has been shown
that antimony is preferentially retained by the SLN
and can be measured in nodal tissue sections by
inductively coupled plasma–mass spectrometry (ICP-
MS).
17 It has also been demonstrated that human
tissue contains only negligible amounts of anti-
mony.
17 ICP-MS enables validation of the SLN
biopsy procedure
26 and can identify false-negative
results attributable to inaccurate SLN removal.
18
Although the morbidity associated with SLN
biopsy is low,
11 it is an invasive procedure, with a
deﬁnite risk of complications and morbidity.
19,20 In
addition, the ﬁnancial implications of SLN biopsy
must be considered. One estimate of the cost of per-
forming a SLN biopsy procedure on an outpatient
basis was US$12,193
21—a high cost for providing
melanoma treatment services to the community. The
development of a minimally invasive technique for
the identiﬁcation of SLN metastases may minimize or
eliminate the morbidity of the procedure and provide
a potential cost beneﬁt. It should be possible to
identify SLNs by preoperative lymphoscintigraphy,
localize the SLNs with ultrasound, and then perform
a percutaneous ﬁne-needle biopsy (FNB) under
ultrasound control.
22 Preliminary studies of proton
magnetic resonance spectroscopy (MRS) analysis of
FNB samples from lymph nodes indicate that this
technique has the capacity to distinguish nodes con-
taining metastatic melanoma from uninvolved nodes
with high sensitivity, speciﬁcity, and accuracy.
22,23 In
addition to accurately determining the tumor-har-
boring status of the lymph node by this technique, it
is also valuable to verify that the sampled lymph node
is a ‘‘true’’ SLN, particularly if it has been assessed as
being free of metastatic tumor.
The objective of this study was to develop a
method for conﬁrming that a FNB specimen was
obtained from a true SLN by measuring the level of
antimony (present in radiocolloid used during pre-
operative lymphoscintigraphy) in the FNB sample by
ICP-MS.
MATERIALS AND METHODS
Instrumentation
All measurements were made with an Agilent
7500ce Inductively Coupled Plasma Mass Spectrom-
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nebulizer, a Quartz-Scott spray chamber (Peltier
cooled, 2C), and an Agilent three-channel peristaltic
pump. The operating conditions were optimized daily
to ensure maximum sensitivity. Typical operating
conditions are summarized in Table 1. The mass
spectrometer was operated in spectrum mode with an
integration time of 300 ms on each of the following
isotopes:
121Sb,
123Sb,
103Ru (internal standard/con-
trol).
Reagents and Chemicals
All reagents used were of the highest purity avail-
able. Seventy percent double-distilled nitric acid, 37%
hydrochloric acid (Arastar), and 30% hydrogen per-
oxide were obtained from Sigma-Aldrich, Australia.
Ultra-high-purity water was produced by passing
distilled water through a Milli-Q deionizing system
(Millipore, Australia).
Standards and Certiﬁed Reference Materials
Certiﬁed reference material GBW 07601 Human
Hair Powder (Langfang, China) was selected because
of its certiﬁed antimony levels. Multiple samples of
the reference material were also analyzed with each
batch of samples and during method development to
ensure the accuracy and precision of the analytic
technique.
SLN Biopsy Procedure
Preoperative lymphoscintigraphy was performed
to identify the node ﬁelds receiving direct lymphatic
drainage. This process involved intradermal injec-
tions of
99 mTc-Sb2S3 around the primary cutaneous
melanoma site, followed by early and delayed imag-
ing with a scintillation camera.
24 The location of the
SLNs was marked on the overlying skin by the nu-
clear medicine physician to assist the surgeon in
locating SLNs during surgery.
The SLN biopsy procedure was performed within
24 hours of the radiocolloid injection, so that residual
radioactivity in lymph nodes could be measured in-
traoperatively with a handheld gamma probe (Navi-
gator GPS, RMD Instruments, Watertown, MA).
Fifteen minutes before the operative procedure,
multiple intradermal injections of Patent Blue V dye
(Guerbet, Roissy, France) were made around the
primary cutaneous melanoma site. SLN identiﬁcation
was based on visualization of the nodal blue dye
staining and results from the preoperative lympho-
scintigraphy, with gamma probe conﬁrmation. The
experimental protocols of this study were approved
by the University of Sydney Ethics Review Board in
accordance with the precepts established by the
Declaration of Helsinki.
FNB Samples
The FNB collection process involved puncturing
the fresh SLN specimen within 30 minutes of its
surgical removal with a 25-gauge needle attached to a
3-mL plastic syringe. Multiple passes were then made
through each quarter of the specimen. A total of 47
FNB samples (from 32 presumptive SLNs and 15
nodes considered to be non-SLNs) were collected. All
samples were placed in polypropylene vials contain-
ing 300 lL of phosphate-buﬀered saline (.27 mM of
KCl, 13.69 mM of NaCl, 1.52 mM of KH2PO4;p H
7.2) made up in perdeuterated water (phosphate-
buffered saline–D2O) and immediately snap-frozen in
liquid nitrogen and stored at )70C.
22
Microwave Digestion Procedure
Each FNB sample was transferred to a polypro-
pylene tube and prepared by the previously described
microwave digestion procedure.
17 Brieﬂy, the sample
was digested in a solution containing 300 lL of nitric
acid, 300 lL of hydrochloric acid, and 500 lLo f
hydrogen peroxide. Each sample was digested ﬁve
times in a 500 W microwave oven on the defrost
setting for 30 seconds each time. The digest was then
quantitatively transferred to a second polypropylene
tube, made up to 10 g with a 1% nitric acid solution,
and assayed by ICP-MS.
Statistical Analysis
The unpaired t-test was used to analyze differences
between the levels of antimony in the FNB digests
TABLE 1. Operating parameters for Agilent 7500ce Induc-
tively Coupled Plasma–Mass Spectrometry
Parameter Condition
Radiofrequency power 1500 W
Sample depth 8 mm
Plasma gas ﬂow 15.0 L min
)1
Carrier gas ﬂow 1.05 L min
)1
Peristaltic pump .15 rps
Sample read delay 60 s
Rinsing time 45 s
Dwell time 100 ms
Replicates 6
rps, revolution per second.
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was considered statistically signiﬁcant.
RESULTS
The certiﬁed concentration of antimony in GBW
07601 is .095 ± .012 lg/g (mean ± SD). Replicate
analyses of reference materials during method vali-
dation and sample analysis gave a mean value of
.088 ± .007 lg/g and a relative standard deviation of
<9%, conﬁrming the accuracy and precision of the
method. The limit of detection (LOD) was evaluated
by the 3r criterion (the LOD is given by mb +3 rb,
where mb is the blank measurement mean and rb is
standard deviation of ﬁve blank measurements) and
found to be .048 parts per billion (ppb).
The matrix-matched calibration standards were in
the range of 0 to 20 ppb and gave an R
2 value of
>.9998 during method validation and sample anal-
ysis. The relative standard deviation of the slopes of
the calibration curves was found to be <10%.
The concentration of antimony in the digested
SLNs and non-SLNs was measured, and the results
are presented in Tables 2 and 3, respectively. The
mean and median concentrations of antimony were
.898 and .451 ppb, respectively, in the SLNs (range,
<LOD)3.248) and .0145 and .0068 ppb in the non-
SLNs (range, <LOD).1159). These results indicate
that the levels of antimony in FNBs from SLNs were
signiﬁcantly greater than from non-SLNs
(P < .00005) (Fig. 1).
DISCUSSION
Current standard clinical management of patients
with primary cutaneous melanoma includes wide lo-
cal excision of the primary tumor and SLN biopsy for
patients considered to be at high risk of having re-
gional node ﬁeld metastases.
25 Technical failures of
TABLE 2. Concentration of antimony (ppb) in ﬁne-needle
biopsy sample digests collected from sentinel lymph nodes
Sample No. Antimony concentration (ppb)
1 <LOD
2 <LOD
3 <LOD
4 <LOD
5 .0666
6 .0979
7 .1738
8 .2985
9 .3020
10 .3085
11 .3257
12 .3807
13 .3812
14 .3864
15 .3903
16 .4045
17 .4971
18 .6079
19 .6407
20 .7243
21 .8582
22 1.091
23 1.438
24 1.444
25 1.724
26 1.760
27 1.847
28 2.013
29 2.150
30 2.298
31 2.756
32 3.248
LOD, limit of detection (.048 ppb).
TABLE 3. Concentration of antimony (ppb) in ﬁne-needle
biopsy sample digests collected from nonsentinel lymph nodes
Sample No. Antimony concentration (ppb)
1 <LOD
2 <LOD
3 <LOD
4 <LOD
5 <LOD
6 <LOD
7 <LOD
8 <LOD
9 <LOD
10 <LOD
11 <LOD
12 <LOD
13 <LOD
14 <LOD
15 .1159
LOD, limit of detection (.048 ppb).
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FIG. 1. Antimony concentration in digested ﬁne-needle biopsy
samples from sentinel lymph nodes and nonsentinel lymph nodes.
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lymphoscintigraphy, sentinel lymphadenectomy, or
histologic evaluation. In such cases, the potential for
disease recurrence in a previously mapped lymph
node basin exists.
6,8–10,12,14
A reliable technique to conﬁrm the identity of a
SLN has the potential to reduce false-negative results
attributable to surgical errors. In a previous study, we
demonstrated that the analysis of antimony in sec-
tioned nodal tissue could be used to distinguish SLNs
and non-SLNs removed from the same nodal basin.
26
This technique can be used within the bounds of
currently used histopathologic protocols and has the
advantage of being applicable to archival parafﬁn-
embedded tissue.
It has also been established that false-negative re-
sults may be caused by the removal of a lymph node
incorrectly classiﬁed as a sentinel lymph node.
18 Be-
cause neither blue dye nor radioisotope persist after
procedures required for microscopic examination,
they cannot be used retrospectively to conﬁrm that
the ‘‘true’’ SLN had been removed. The only other
reported method to conﬁrm SLN identity involves
the injection, along with the blue dye, of carbon
particles that are retained by the node.
27,28 However,
these large, dense carbon particles may hinder opti-
mal histologic examination by obscuring metastatic
melanoma cells. As far as we are aware, this method
is not in routine clinical use.
FNB digests from four nodes presumed to be
SLNs (13%) were found to contain extremely low
levels of antimony, below the LOD. In a previous
study, we also identiﬁed SLNs that contained ex-
tremely low levels of antimony.
26 The most likely
reason for the low antimony levels would be inac-
curate classiﬁcation of the node that had been re-
moved as a SLN, when it is in fact a non-SLNs.
Other possible explanations to account for the low
antimony levels include variable distribution of
antimony throughout the node, limited migration of
the colloid to the lymph nodes, or tumor deposits
preventing colloid uptake. Haigh et al.
27 investi-
gated the distribution of carbon dye in SLNs and
found a high concentration of carbon particles
around the point of entry of afferent lymphatic
channels. It is likely that antimony exhibits an
analogous distribution pattern. If so, FNB samples
that fail to include this region of the SLN may
contain falsely low antimony levels. In view of these
factors, it would be useful to set a criterion stan-
dard for classifying a given node as sentinel or not
on the basis of antimony levels assessed by ICP-
MS.
However, deﬁning such a criterion on the basis of
our small sample set is diﬃcult. In a previous study,
we assessed antimony levels in archival tissue sections
of paired tumor-positive SLNs and tumor-negative
non-SLNs removed from the same regional node ﬁeld
during the same operative procedure from individual
patients.
26 The aims of this study were to determine
whether antimony concentrations could be used to
conﬁrm whether removed SLNs were ‘‘true’’ SLNs
and to differentiate SLNs from non-SLNs. The
median concentration of antimony in the SLNs was
.526 ppb and in non-SLNs was .043 ppb (P = .004).
By using a cutoff point of .18 ppb (the median con-
centration of antimony in all SLNs and non-SLNs) to
differentiate SLNs from non-SLNs, 20 of 24 SLNs
and 20 of 24 non-SLNs were correctly identiﬁed by
the SLN biopsy procedure.
Although SLN biopsy is a highly accurate method
for staging regional lymph nodes, it is an invasive
surgical procedure that is costly and is associated
with an inherent risk of complication and morbid-
ity.
19,20 Pathologic assessment of SLNs is laborious,
time-consuming, and costly, and involves examina-
tion of multiple hematoxylin and eosin–stained hist-
opathologic sections as well as sections stained with
immunohistochemical techniques. The development
of a rapid nonsurgical technique that allows detection
of metastatic tumor deposits would be of great ben-
efit. It would eliminate the need for surgical excision
of lymph nodes and reduce the complexity of path-
ologic assessment of SLNs. However, to ensure that
potential false-negative results are minimized, it is
imperative to ensure the accuracy of SLN identifi-
cation.
Several studies have identiﬁed proton MRS as a
candidate for the nonsurgical assessment of lymph
nodes.
22,23 The technique monitors changes in the
chemical composition of cells during tumor devel-
opment and can identify differences that are not
morphologically discernible. In these studies, the
spectra collected from SLN FNB samples harboring
tumor cells contain choline and taurine peaks, which
are absent in disease-free samples.
23 Another sensitive
technique for the detection of melanoma metastases
in SLNs is the assessment of tyrosinase mRNA by
reverse transcriptase–polymerase chain reaction (RT-
PCR).
29,30 However, as far as we are aware, RT-PCR
assessment of tyrosinase mRNA has not been studied
in FNB samples of SLNs. A major potential problem
of RT-PCR analysis of FNB samples of SLNs is the
issue of false-positive and false-negative results in
such specimens and this would need to be assessed
before the technique could be used in clinical practice.
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dence that determining antimony levels in FNB
specimens by ICP-MS can conﬁrm SLN identity and
can diﬀerentiate SLNs from non-SLNs. This tech-
nique may be a useful adjunct to other techniques
assessing tumor-harboring status of SLNs on FNB
specimens such as MRS. Potentially, proton MRS
analysis of a FNB from a node conﬁrmed to be a true
SLN by ICP-MS could provide a reliable method for
determining the tumor-harboring status of SLNs.
Although the results are promising and raise the
possibility that SLN assessment may be performed on
FNB specimens (rather than histologic specimens of
excised SLNs) in the future, further validation studies
are necessary before such techniques are used in
widespread clinical practice. Furthermore, the highly
specialized and expensive nature of the equipment
used for ICP-MS will likely limit the technique to
specialist centers.
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